Collecting blood samples to improve lung cancer diagnosis
Sample Collection for The Integration and Analysis of Data Using Artificial Intelligence to Improve Patient Outcomes With Thoracic Diseases
This study is collecting blood samples to see if new methods can help doctors diagnose lung cancer earlier and more accurately.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 5000 (estimated) |
| Ages | 55 Years to 75 Years |
| Sex | All |
| Sponsor | University of Oxford Academic / other |
| Locations | 11 sites (Oxford, Oxfordshire and 10 other locations) |
| Trial ID | NCT05368298 on ClinicalTrials.gov |
What this trial studies
This observational study aims to collect blood samples from participants to develop innovative methods for detecting and diagnosing lung health issues, particularly lung cancer. By linking the results with data from the DART study, the research will utilize artificial intelligence algorithms to enhance the accuracy and speed of lung health assessments. The goal is to facilitate earlier diagnosis and treatment of lung cancer, ultimately improving patient outcomes.
Who should consider this trial
Good fit: Ideal candidates include patients with pulmonary nodules detected on CT scans during lung cancer screening who require further investigation.
Not a fit: Patients without pulmonary nodules or those not undergoing lung cancer screening may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to earlier and more accurate diagnoses of lung cancer, allowing for more effective treatment options.
How similar studies have performed: Other studies utilizing artificial intelligence for lung cancer diagnosis have shown promising results, indicating potential for success in this approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Patient suitability will be assessed against the below criteria by the clinical teams managing the patients. Inclusion Criteria: 1. Patients with a pulmonary nodule or nodule(s) detected on a CT scan performed as part of Lung Cancer Screening from the Lung Health Check centres, that require further investigation with a PET-CT scan, and / or biopsy, and / or resection 2. Willing and able to give informed consent Exclusion Criteria: * None -
Where this trial is running
Oxford, Oxfordshire and 10 other locations
- Lung Health Check: Oxford - Churchill Hospital, OUH — Oxford, Oxfordshire, United Kingdom (Recruiting)
- Lung Health Check Centre: Royal Sussex — Brighton, United Kingdom (Recruiting)
- Lung Health Check Centre: North Bristol — Bristol, United Kingdom (Recruiting)
- Lung Health Check Centre: Gateshead — Gateshead, United Kingdom (Recruiting)
- Lung Health Check Centre: Corby & Kettering — Kettering, United Kingdom (Recruiting)
- Lung Health Check Centre: Cheshire & Merseyside — Liverpool, United Kingdom (Recruiting)
- Lung Health Check Centre: RM Partners — London, United Kingdom (Recruiting)
- Lung Health Check Centre: Newcastle & Gateshead — Newcastle, United Kingdom (Recruiting)
- Lung Health Check Centre: Plymouth — Plymouth, United Kingdom (Recruiting)
- Lung Health Check Centre: Stoke — Stoke, United Kingdom (Recruiting)
- Lung Health Check Centre: South Tyneside and Sunderland — Sunderland, United Kingdom (Recruiting)
Study contacts
- Principal investigator: Richard Lee — Royal Marsden NHS Foundation Trust
- Study coordinator: Rachel Austin
- Email: octo-scoot@oncology.ox.ac.uk
- Phone: 01865 617420
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.